article · Malaria Journal
Triple artemisinin-based combination therapy, known as TACT, presents new advantages over standard artemisinin-based combination therapy in addressing malaria. While standard therapies are recognised for cost-effectiveness and lower adverse events, TACT tackles drug resistance, provides a broader spectrum of action, and lowers the likelihood of treatment failure. Furthermore, these triple therapies can be adapted to regional requirements to strengthen disease control. Realising the potential of TACT requires overcoming accessibility barriers, particularly across resource-constrained areas where malaria transmission remains highest. Achieving wide adoption relies on joint initiatives among governments, international bodies, pharmaceutical manufacturers, research institutions, and local communities. Sustainable pricing models, robust distribution systems, and public-private partnerships are needed alongside educational campaigns to dispel persistent malaria myths, ensuring that these advanced therapies reach vulnerable populations effectively.
Drug resistance poses an ongoing threat to malaria control efforts. Triple artemisinin-based combinations offer an improved treatment option capable of countering resistance and lowering failure rates. Securing their impact requires addressing cost, distribution, and community awareness, ensuring that effective antimalarial medicines remain accessible to vulnerable populations in high-burden, resource-limited regions.
TACT represents a pharmaceutical application aimed at healthcare providers, national health programmes, and patients in malaria-endemic regions. Real-world delivery depends on partnerships involving pharmaceutical companies, research institutions, and governments to establish sustainable pricing models and reliable supply chains. While the clinical concept is established, widespread market entry requires public-private collaboration and targeted educational initiatives to secure regulatory acceptance, distribution, and community uptake.
AI-generated from the published abstract. Always read the original work before citing.
This paper examines the far-reaching implications of Triple Artemisinin-Based Combination Therapy (TACT) in the global battle against malaria. Artemisinin-Based Combination Therapy (ACT) is recognized for its cost-effectiveness, lower likelihood of adverse events, and widespread acceptance by patients and healthcare providers. However, TACT introduces novel dimensions to the fight against malaria that make them a superior choice in several aspects. TACT has been demonstrated to address resistance, offer a broader spectrum of action, reduce the risk of treatment failure, and can be tailored to meet regional needs, strengthening the global effort to combat malaria. However, maximizing these benefits of TACT depends on accessibility, particularly in resource-limited regions where malaria is most prevalent. Collaborative efforts among stakeholders, sustainable pricing strategies, efficient supply chains, and public-private partnerships are essential to ensure that TACT reaches needy populations. Moreover, dispelling prevalent malaria myths through health education campaigns is critical in this endeavour. The paper underscores the significance of collaborative initiatives and partnerships among governments, international organizations, research institutions, acadaemia, pharmaceutical companies, and local communities. Together, these efforts can pave the way for the acceptance, adoption, and success of TACT, ultimately advancing the global goal of a malaria-free world.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s12936-024-04844-y
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
